BACKGROUND: Warfarin inhibits vitamin K-dependent coagulation factors. Being fat-soluble, the availability of vitamin K may vary according to body fat. We hypothesized that body mass index (BMI), a proxy of body fat, may interact with vitamin K intake in determining a warfarin maintenance (WM) dose. METHODS: Patients with data on vitamin K intake, potential confounders and WM dose (n = 172) were included in linear regression models to test whether BMI modifies the relation between vitamin K intake and WM dose. RESULTS: Warfarin loading dose correlated with the maintenance dose (r = 0.36, p < 0.0001) but was not significantly associated with WM dose in analyses adjusted for vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) genotypes. In fully adjusted models, BMI was associated (p = 0.001) with WM dose but vitamin K was only marginally positively associated (p = 0.06) with WM dose. We found no interaction (p > 0.05) between BMI and vitamin K intake with regard to WM dose. Inclusion of vitamin K intake in the model only slightly improved the amount of variance (1.1%) explained by age, gender, BMI, race, physical activity, energy intake and VKORC1 and CYP2C9 genotypes. CONCLUSION: Our data suggest that body fat does not affect the relation between vitamin K intake and WM dose.
BACKGROUND:Warfarin inhibits vitamin K-dependent coagulation factors. Being fat-soluble, the availability of vitamin K may vary according to body fat. We hypothesized that body mass index (BMI), a proxy of body fat, may interact with vitamin K intake in determining a warfarin maintenance (WM) dose. METHODS:Patients with data on vitamin K intake, potential confounders and WM dose (n = 172) were included in linear regression models to test whether BMI modifies the relation between vitamin K intake and WM dose. RESULTS:Warfarin loading dose correlated with the maintenance dose (r = 0.36, p < 0.0001) but was not significantly associated with WM dose in analyses adjusted for vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) genotypes. In fully adjusted models, BMI was associated (p = 0.001) with WM dose but vitamin K was only marginally positively associated (p = 0.06) with WM dose. We found no interaction (p > 0.05) between BMI and vitamin K intake with regard to WM dose. Inclusion of vitamin K intake in the model only slightly improved the amount of variance (1.1%) explained by age, gender, BMI, race, physical activity, energy intake and VKORC1 and CYP2C9 genotypes. CONCLUSION: Our data suggest that body fat does not affect the relation between vitamin K intake and WM dose.
Authors: M Kyla Shea; Sarah L Booth; Caren M Gundberg; James W Peterson; Catherine Waddell; Bess Dawson-Hughes; Edward Saltzman Journal: J Nutr Date: 2010-03-17 Impact factor: 4.798
Authors: Nita A Limdi; Mohit A Limdi; Larisa Cavallari; Aaron M Anderson; Michael R Crowley; Melissa F Baird; Michael Allon; T Mark Beasley Journal: Am J Kidney Dis Date: 2010-08-14 Impact factor: 8.860
Authors: Cordula Meyer zu Schwabedissen; Vera Mevissen; Fabian Schmitz; Seth Woodruff; Georg Langebartels; Thomas Rau; Klaus Zerres; Rainer Hoffmann; Jan R Ortlepp Journal: Eur J Clin Pharmacol Date: 2006-07-18 Impact factor: 2.953
Authors: Katie B Tellor; Steffany N Nguyen; Amanda C Bultas; Anastasia L Armbruster; Nicholas A Greenwald; Abigail M Yancey Journal: Ther Adv Cardiovasc Dis Date: 2018-06-19